Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study.

Trial Profile

Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2016

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Haematological malignancies; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2016 According to Takeda Pharmaceutical media release, European Commission has approved a Type II variation for ADCETRIS (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL). EC decision followed the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015.
    • 14 May 2013 Preliminary data were previously reported at the 2011 American Society of Hematology (ASH) Annual Meeting and at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, according to Seattle Genetics.
    • 14 May 2013 The US FDA accepted for filing a supplement to the Biologics License Application supporting the use of brentuximab vedotin for retreatment and extended duration based on the results of this study, according to a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top